Insulin with 40 hours of duration promises fewer injections to patients with diabetes
Approved by the European Medicines Commission, this insulin promises to revolutionize the treatment of diabetes. This is because its action is about 42 hours and presents a profile of stability in glucose control. The result is that the patient can apply it once every two days on average, in addition to allowing flexibility in application schedules. For comparison purposes: NPH insulin, which is the most commonly prescribed in Brazil, often requires up to three daily applications, and in some people it is important that the dose be monitored closely to avoid hypoglycaemia. insulin Degludec is the control of glycated hemoglobin in a similar way to insulin Glargine (which is a long acting insulin - applied once a day) both in patients with type 1 diabetes and in those with type 2 diabetes. Another advantage is that it presents reduced risk of episodes of hypoglycemia.
Continuing with the novelties, in addition to being marketed in isolation, Degludec insulin will also be available in combination with Aspart insulin. The latter is an ultra-fast insulin, which allows the application of the doses also before meals.
Degludec insulin will be available in pens for application. Its shelf-life is 30 months after the date of manufacture and, like other insulins, should be stored in the refrigerator between 2 ° C and 8 ° C when the bottle is closed. Once opened, it can be stored for up to eight weeks without the need for refrigeration if the ambient temperature does not exceed 30 ° C.
One of the major problems faced in treating diabetes is non-adherence to treatment, because insulin applications are , for most people, very uncomfortable. The possibility of reducing the number of applications in the week and ensuring a more stable control of the disease is a dream that is coming true.
Agência Saúde - Brazil is a pioneer in the study of the relationship of Zika virus with microcephaly and has advanced with agility in the investigations. These evaluations were made during the 138th Session of the Executive Board of the World Health Organization (WHO) held this Thursday (28) in Geneva, Switzerland.
Several studies have already shown that eating too much red meat can be harmful to health. Now it has been pointed out as a risk factor for bowel cancer. This is revealed by a review of six scientific studies that will be presented at the American Cancer Society congress in the United States under the leadership of Alexandra Paola Zandonai, a specialist in oncology nursing at the University of São Paulo (USP).